MA38816A - Sulfamidase modifiée et sa production - Google Patents

Sulfamidase modifiée et sa production

Info

Publication number
MA38816A
MA38816A MA038816A MA38816A MA38816A MA 38816 A MA38816 A MA 38816A MA 038816 A MA038816 A MA 038816A MA 38816 A MA38816 A MA 38816A MA 38816 A MA38816 A MA 38816A
Authority
MA
Morocco
Prior art keywords
sulfamidase
modified
modified sulfamidase
production
mammal
Prior art date
Application number
MA038816A
Other languages
English (en)
Other versions
MA38816B1 (fr
Inventor
Charlotta Berghard
Erik Nordling
Gelius Stefan Svensson
Agneta Tjernberg
Original Assignee
Swedish Orphan Biovitrum Ab Publ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Swedish Orphan Biovitrum Ab Publ filed Critical Swedish Orphan Biovitrum Ab Publ
Publication of MA38816A publication Critical patent/MA38816A/fr
Publication of MA38816B1 publication Critical patent/MA38816B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y310/00—Hydrolases acting on sulfur-nitrogen bonds (3.10)
    • C12Y310/01—Hydrolases acting on sulfur-nitrogen bonds (3.10) acting on sulfur-nitrogen bonds (3.10.1)
    • C12Y310/01001—N-Sulfoglucosamine sulfohydrolase (3.10.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La présente invention concerne une sulfamidase modifiée, une composition comprenant une sulfamidase modifiée, ainsi que des procédés de préparation d'une sulfamidase modifiée et l'utilisation thérapeutique d'une telle sulfamidase. En particulier, la présente invention concerne une sulfamidase modifiée ne comprenant pratiquement pas d'épitopes pour des récepteurs de reconnaissance de glycane, permettant ainsi le transport de ladite sulfamidase à travers la barrière hémato-encéphalique d'un mammifère, ladite sulfamidase ayant une activité catalytique dans le cerveau dudit mammifère.
MA38816A 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production MA38816B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14162996 2014-04-01
EP15713502.1A EP2970413B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production
PCT/EP2015/057256 WO2015150490A1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et son procédé de production

Publications (2)

Publication Number Publication Date
MA38816A true MA38816A (fr) 2016-01-20
MA38816B1 MA38816B1 (fr) 2018-10-31

Family

ID=50389999

Family Applications (1)

Application Number Title Priority Date Filing Date
MA38816A MA38816B1 (fr) 2014-04-01 2015-04-01 Sulfamidase modifiée et sa production

Country Status (30)

Country Link
US (2) US9982243B2 (fr)
EP (2) EP2970413B1 (fr)
JP (1) JP6594896B2 (fr)
KR (1) KR20160138282A (fr)
CN (1) CN106414727A (fr)
AU (1) AU2015239126B2 (fr)
BR (1) BR112016022333A2 (fr)
CA (1) CA2943140A1 (fr)
CL (1) CL2016002469A1 (fr)
CY (1) CY1120697T1 (fr)
DK (1) DK2970413T3 (fr)
ES (1) ES2687262T3 (fr)
HK (1) HK1231510A1 (fr)
HR (1) HRP20181507T1 (fr)
HU (1) HUE039691T2 (fr)
IL (1) IL247978A0 (fr)
LT (1) LT2970413T (fr)
MA (1) MA38816B1 (fr)
MX (1) MX368947B (fr)
PH (1) PH12016501812A1 (fr)
PL (1) PL2970413T3 (fr)
PT (1) PT2970413T (fr)
RS (1) RS57842B1 (fr)
RU (1) RU2708026C2 (fr)
SA (1) SA516371859B1 (fr)
SG (1) SG11201608025QA (fr)
SI (1) SI2970413T1 (fr)
UA (1) UA120432C2 (fr)
WO (1) WO2015150490A1 (fr)
ZA (1) ZA201606492B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2970413T1 (sl) 2014-04-01 2018-10-30 Swedish Orphan Biovitrum Ab (Publ) Modificirana sulfamidaza in proizvodja le-te
JP2018535654A (ja) * 2015-10-01 2018-12-06 スウェディッシュ オーファン バイオビトラム アクティエボラーグ （ペーウーベーエル） 修飾リソソームタンパク質とその製造
SG11202002730XA (en) 2017-10-02 2020-04-29 Denali Therapeutics Inc Fusion proteins comprising enzyme replacement therapy enzymes
WO2019145500A1 (fr) 2018-01-26 2019-08-01 Swedish Orphan Biovitrum Ab (Publ) Méthode de traitement
WO2020047282A1 (fr) 2018-08-29 2020-03-05 University Of Copenhagen Enzymes lysosomales modifiées par glyco-ingénierie basée sur les cellules
EP3741867A1 (fr) 2019-05-24 2020-11-25 Swedish Orphan Biovitrum AB (Publ) Dosage d'activité de sulfatase
KR20230086703A (ko) 2020-10-14 2023-06-15 데날리 테라퓨틱스 인크. 설포글루코사민 설포하이드롤라제 효소를 포함하는 융합 단백질 및 이의 방법

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5863782A (en) 1995-04-19 1999-01-26 Women's And Children's Hospital Synthetic mammalian sulphamidase and genetic sequences encoding same
EP1378525A3 (fr) 1996-06-07 2004-01-14 Neorx Corporation Anticorps humanisés qui se lient à l'antigène relié par l'anticorp NR-LU-13 et leur utilisation dans des méthodes de ciblage
US7560424B2 (en) 2001-04-30 2009-07-14 Zystor Therapeutics, Inc. Targeted therapeutic proteins
US8008252B2 (en) 2001-10-10 2011-08-30 Novo Nordisk A/S Factor VII: remodeling and glycoconjugation of Factor VII
JP2005506340A (ja) 2001-10-16 2005-03-03 シムバイオンティクス インコーポレイテッド 血液脳関門をわたる過小グリコシル化タンパク質の標的化のための方法および組成物
MXPA05000063A (es) 2002-07-01 2005-04-08 Kenneth S Warren Inst Inc Citocinas recombinantes protectoras de tejido y acidos nucleicos que las codifican para la proteccion, restauracion y mejora de celulas, tejidos y organos respondedores.
EP2139912A2 (fr) * 2007-03-06 2010-01-06 Saint Louis University Enzyme modifiée et procédé de traitement
US8128925B2 (en) * 2008-01-18 2012-03-06 Biomarin Pharmaceutical Inc. Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereof
EP2394667A1 (fr) * 2010-06-10 2011-12-14 Laboratorios Del Dr. Esteve, S.A. Vecteurs et séquences pour le traitement de maladies
JP6023073B2 (ja) * 2010-12-22 2016-11-09 フォンダッツィオーネ・テレソン ムコ多糖症におけるｃｎｓ病変を処置するための治療戦略
US9155784B2 (en) * 2011-06-20 2015-10-13 Icahn School Of Medicine At Mount Sinai Anti-TNF-α therapy for the mucopolysaccharidoses and other lysosomal disorders
WO2014194427A1 (fr) 2013-06-06 2014-12-11 Angiochem Inc. Protéines de fusion iduronate-2-sulfatase ciblées
US20140377246A1 (en) 2013-06-19 2014-12-25 Carol Ann Foundation and International Morquio Organization Enzyme replacement therapy for treating mps vii related bone lesions using a chemically modified enzyme
SI2970413T1 (sl) 2014-04-01 2018-10-30 Swedish Orphan Biovitrum Ab (Publ) Modificirana sulfamidaza in proizvodja le-te

Also Published As

Publication number Publication date
US20180320152A1 (en) 2018-11-08
CN106414727A (zh) 2017-02-15
DK2970413T3 (en) 2018-10-15
SG11201608025QA (en) 2016-10-28
HK1231510A1 (zh) 2017-12-22
CA2943140A1 (fr) 2015-10-08
JP6594896B2 (ja) 2019-10-23
KR20160138282A (ko) 2016-12-02
RU2016140844A3 (fr) 2018-10-11
SA516371859B1 (ar) 2019-01-17
ES2687262T3 (es) 2018-10-24
RU2016140844A (ru) 2018-05-10
AU2015239126B2 (en) 2019-05-02
CY1120697T1 (el) 2019-12-11
WO2015150490A1 (fr) 2015-10-08
RS57842B1 (sr) 2018-12-31
HUE039691T2 (hu) 2019-01-28
MX2016012910A (es) 2017-07-14
PH12016501812A1 (en) 2017-07-24
LT2970413T (lt) 2018-10-10
BR112016022333A2 (pt) 2017-08-15
US20160230155A1 (en) 2016-08-11
PL2970413T3 (pl) 2018-12-31
CL2016002469A1 (es) 2017-12-15
ZA201606492B (en) 2019-02-27
PT2970413T (pt) 2018-10-23
HRP20181507T1 (hr) 2018-11-16
US9982243B2 (en) 2018-05-29
EP2970413B1 (fr) 2018-07-04
EP3401325A1 (fr) 2018-11-14
JP2017514462A (ja) 2017-06-08
RU2708026C2 (ru) 2019-12-03
AU2015239126A1 (en) 2016-10-27
MA38816B1 (fr) 2018-10-31
MX368947B (es) 2019-10-22
EP2970413A1 (fr) 2016-01-20
SI2970413T1 (sl) 2018-10-30
UA120432C2 (uk) 2019-12-10
IL247978A0 (en) 2016-11-30

Similar Documents

Publication Publication Date Title
MA38816A (fr) Sulfamidase modifiée et sa production
MA43518A (fr) 3-azabicyclo[3.1.0]hexanes substitués servant d'inhibiteurs de cétohexokinase
MD3555064T2 (ro) Agoniști ai receptorului GLP-1 și utilizările acestora
MD3273992T2 (ro) Anticorpi pentru ICOS
MA40576B1 (fr) Anticorps et immunoconjugués anti-her2
EA201692201A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
EA201692177A1 (ru) Соединения и композиции в качестве агонистов toll-подобного рецептора 7
MA44594B1 (fr) Anticorps anti-ctla-4 et méthodes d'utilisation de ceux-ci
BR112014026755A2 (pt) anticorpos contra claudin 18.2 úteis no diagnóstico de câncer
EA201791310A1 (ru) Химерные антигенные рецепторы к bcma
EA201692271A1 (ru) Терапевтически активные соединения и способы их применения
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
EA201590174A1 (ru) Иммуноконъюгаты, содержащие анти-cd22 антитела
EA201491811A1 (ru) АНТИ-LgR5 АНТИТЕЛА И ИММУНОКОНЪЮГАТЫ
MX2018013234A (es) Sintesis de indazoles.
FR2975600B1 (fr) Agents pour le traitement de tumeurs
TR201903026T4 (tr) S100a4 anti̇korlari ve bunlarin terapöti̇k kullanimlari.
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
WO2015171558A3 (fr) Benzènesulfonamido et composés apparentés utilisés en tant qu'agonistes de rorγ et pour le traitement de maladie
EA201791096A1 (ru) 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139
EA201691982A1 (ru) 5,6-дизамещенные пиридин-2-карбоксамиды в качестве агонистов каннабиноидных рецепторов
WO2016057683A3 (fr) Nouveaux anticorps anti-nodaux et méthodes d'utilisation de ceux-ci
UY34842A (es) Formulaciones estabilizadas que contienen anticuerpos anti-dll4
WO2017066796A3 (fr) Modulateurs de maladies impliquant des télomères
WO2015022669A3 (fr) Procédés de typage d'allèles de hla